Epothilone B enhances Class i HLA and HLA-A2 surface molecule expression in ovarian cancer cells

Gynecologic Oncology

Volumn 122, Issue 3, 2011, Pages 625-631

  Pellicciotta, Ilenia ^a,b   Yang, Chia Ping Huang ^a   Goldberg, Gary L ^a   Shahabi, Shohreh ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b DANBURY HOSPITAL   (United States)

Author keywords

Epothilone B; Hey cells; HLA Class I; Ovarian cancer; Taxol; Vinblastine

Indexed keywords

ALPHA INTERFERON; EPOTHILONE B; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; PACLITAXEL; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG MECHANISM; DRUG RESISTANCE; HUMAN; HUMAN CELL; IC 50; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA TRANSCRIPTION;

CELL LINE, TUMOR; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOTHILONES; FEMALE; HLA ANTIGENS; HLA-A2 ANTIGEN; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; RNA, MESSENGER; TUBULIN MODULATORS; VINBLASTINE;

EID: 80955179580     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.05.007     Document Type: Article

References (53)

1. T.C. Chou, X. Zhang, Z.Y. Zhong, Y. Li, L. Feng, and S. Eng Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones Proc Natl Acad Sci 105 35 Sep 2 2008 13157 13162
2. M.N. Fornier Ixabepilone, first in a new class of antineoplastic agents: the natural epothilones and their analogues Clin Breast Cancer 2007 757 763 (Pubitemid 350086120)
3. S. Goodin Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer Am J Health Syst Pharm 65 2008 2017 2026
4. H.M. McDaid, S. Mani, H.J. Shen, F. Muggia, D. Sonnichsen, and S.B. Horwitz Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study Clin Cancer Res 8 2002 2035 2043 (Pubitemid 34753571)
5. D. Donovan, and L.T. Vahdat Epothilones: clinical update and future directions Oncology (Williston Park) 22 2008 408 416
6. R.J. Kowalski, P. Giannakakou, and E. Hamel Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol) J Biol Chem 272 1997 2534 2541 (Pubitemid 27058547)
7. M. Harrison, and C. Swanton Epothilones and new analogues of the microtubule modulators in taxane-resistant disease Expert Opin Investig Drugs 17 2008 523 546 (Pubitemid 351578170)
8. K. De Geest, J.A. Blessing, R.T. Morris, S.D. Yamada, B.J. Monk, and S.L. Zweizig Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study J Clin Oncol 28 1 Jan 1 2010 149 153
9. D. Paik, E. Cocco, S. Bellone, F. Casagrande, M. Bellone, and E.E. Siegel Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro Gynecol Oncol 119 1 Oct 2010 140 145
10. E. Sato, S.H. Olson, J. Ahn, B. Bundy, H. Nishikawa, and F. Qian Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer Proc Natl Acad Sci U S A 102 51 Dec 20 2005 18538 18543 (Pubitemid 43011261)
11. S. Kondratiev, E. Sabo, E. Yakirevich, O. Lavie, and M.B. Resnick Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma Clin Cancer Res 10 13 Jul 1 2004 4450 4456 (Pubitemid 38878888)
12. O. Nakano, M. Sato, Y. Naito, K. Suzuki, S. Orikasa, and M. Aizawa Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity Cancer Res 61 13 Jul 1 2001 5132 5136 (Pubitemid 32681545)
13. F.M. Marincola, E.M. Jaffee, D.J. Hicklin, and S. Ferrone Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance Adv Immunol 74 2000 181 273
14. M. Shehata, A. Mukherjee, S. Deen, A. Al-Attar, L.G. Durrant, and S. Chan Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy Br J Cancer 101 8 Oct 20 2009 1321 1328
15. H. Norell, M. Carlsten, T. Ohlum, K.J. Malmberg, G. Masucci, and K. Schedvins Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity Cancer Res 66 12 Jun 15 2006 6387 6394
16. L. He, C.P. Yang, and S.B. Horwitz Mutations in beta-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines Mol Cancer Ther 1 2001 3 10
17. S. Shahabi, C.P. Yang, G.L. Goldberg, and S.B. Horwitz Epothilone B enhances surface EpCAM expression in ovarian cancer Hey cells Gynecol Oncol 119 2 Nov 2010 345 350
18. T.C. Hamilton Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors Cancer Res 43 1983 5379 5389 (Pubitemid 14230154)
19. K.H. Altmann, and K. Memmert Epothilones as lead structures for new anticancer drugs-pharmacology, fermentation, and structure-activity- relationships Prog Drug Res 66 273 2008 275 334 Review
20. F. Belardelli Role of interferons and other cytokines in the regulation of the immune response APMIS 103 3 Mar 1995 161 179
21. J. Fayen, J.H. Huang, S. Ferrone, and M.L. Tykocinski Negative signaling by anti-HLA class I antibodies is dependent upon two triggering events Int Immunol 10 9 Sep 1998 1347 1358 (Pubitemid 28414340)
22. A. Garcia-Lora, I. Algarra, and F. Garrido MHC class I antigens, immune surveillance, and tumor immune escape J Cell Physiol 195 3 Jun 2003 346 355 Review (Pubitemid 36529863)
23. G. Ljunggren, and D.J. Anderson Cytokine induced modulation of MHC class I and class II molecules on human cervical epithelial cells J Reprod Immunol 38 2 Jul 1998 123 138 (Pubitemid 28342649)
24. D.J. Hicklin, F.M. Marincola, and S. Ferrone HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story Mol Med Today 5 4 Apr 1999 178 186 Review (Pubitemid 29279236)
25. B. Seliger, T. Cabrera, F. Garrido, and S. Ferrone HLA class I antigen abnormalities and immune escape by malignant cells Semin Cancer Biol 12 1 Feb 2002 3 13 Review (Pubitemid 34087893)
26. B. Yu, S. Kusmartsev, and F. Cheng Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer Clin Cancer Res 9 2003 285 294 (Pubitemid 36109745)
27. A.K. Nowak, B.W. Robinson, and R.A. Lake Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors Cancer Res 63 2003 4490 4496 (Pubitemid 36951021)
28. R. Kaneno, G.V. Shurin, I.L. Tourkova, and M.R. Shurin Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations J Transl Med 7 Jul 10 2009 58
29. Viviana †. Marin-Esteban, Dominique Charron, Catherine (*) Gelin, and Nuala (*) Mooney Chemotherapeutic agents targeting the tubulin cytoskeleton modify LPS-induced cytokine secretion by dendritic cells and increase antigen presentation J Immunother Issue 33 4 May 2010 364 370
30. P. Braly, C.F. Nicodemus, C. Chu, Y. Collins, R. Edwards, and A. Gordon The immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer J Immunother 32 1 Jan 2009 54 65
31. M.H. Andersen, N. Junker, E. Ellebaek, I.M. Svane, and P. Thor Straten Therapeutic cancer vaccines in combination with conventional therapy J Biomed Biotechnol 2010 2010 237623
32. H.J. Steer, R.A. Lake, A.K. Nowak, and B.W. Robinson Harnessing the immune response to treat cancer Oncogene 29 48 Dec 2 2010 6301 6313
33. G.V. Shurin, I.L. Tourkova, R. Kaneno, and M.R. Shurin Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism J Immunol 183 1 Jul 1 2009 137 144
34. R.A. Lake, and B.W. Robinson Immunotherapy and chemotherapy-a practical partnership Nat Rev Cancer 5 5 May 2005 397 405 Review
35. A.K. Nowak, R.A. Lake, and B.W. Robinson Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv Drug Deliv Rev 58 8 Oct 1 2006 975 990 Review (Pubitemid 44780907)
36. W.M. Liu, D.W. Fowler, P. Smith, and A.G. Dalgleish Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses Br J Cancer 102 1 Jan 5 2010 115 123
37. G.E. Peoples, J.M. Gurney, M.T. Hueman, M.M. Woll, G.B. Ryan, and C.E. Storrer Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients J Clin Oncol 23 30 Oct 20 2005 7536 7545 (Pubitemid 46291817)
38. C. Yee, J.A. Thompson, D. Byrd, S.R. Riddell, P. Roche, and E. Celis Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells Proc Natl Acad Sci U S A 99 25 Dec 10 2002 16168 16173 (Pubitemid 35462767)
39. L. De Petris, K. Bergfeldt, and C. Hising Correlation between HLA-A2 gene frequency, latitude, ovarian, and prostate cancer mortality rates Med Oncol 21 2004 49 52 (Pubitemid 38491329)
40. V. Ramakrishna, M.M. Ross, M. Petersson, C.C. Gatlin, C.E. Lyons, and C.L. Miller Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells Int Immunol 15 6 Jun 2003 751 763 (Pubitemid 36675806)
41. J. Matsuzaki, F. Qian, I. Luescher, S. Lele, G. Ritter, and P.A. Shrikant Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1 Cancer Immunol Immunother 57 8 Aug 2008 1185 1195
42. F. Moschella, E. Proietti, I. Capone, and F. Belardelli Combination strategies for enhancing the efficacy of immunotherapy in cancer patients Ann N Y Acad Sci 1194 Apr 2010 169 178
43. R.T. Penson, K. Kronish, Z. Duan, A.J. Feller, P. Stark, and S.E. Cook Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel Int J Gynecol Cancer 10 2000 33 41 (Pubitemid 30219476)
44. G.V. Shurin, I.L. Tourkova, and M.R. Shurin Low-dose chemotherapeutic agents regulate small Rho GTPase activity in dendritic cells J Immunother 31 2008 491 499
45. Y. Wang, X.L. Niu, Y. Qu, J. Wu, Y.Q. Zhu, and W.J. Sun Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells Cancer Lett 295 1 Sep 1 2010 110 123
46. K.S. Rath, H.M. Funk, M.C. Bowling, W.E. Richards, and A.F. Drew Expression of soluble interleukin-6 receptor in malignant ovarian tissue Am J Obstet Gynecol 203 3 Sep 2010 230.e1-8
47. D.S. Hong, L.S. Angelo, and R. Kurzrock Interleukin-6 and its receptor in cancer: implications for translational therapeutics Cancer 110 2007 1911 1928 (Pubitemid 350036849)
48. G. Trinchieri, and P. Scott Interleukin-12: a proinflammatory cytokine with immunoregulatory functions Res Immunol 146 7-8 Sep-Oct 1995 423 431 (Pubitemid 26054833)
49. S.M. Santini, C. Lapenta, L. Santodonato, G. D'Agostino, F. Belardelli, and M. Ferrantini IFN-alpha in the generation of dendritic cells for cancer immunotherapy Handb Exp Pharmacol 188 2009 295 317
50. L. Pace, S. Vitale, B. Dettori, C. Palombi, V. La Sorsa, and F. Belardelli APC activation by IFN-alpha decreases regulatory T cell and enhances Th cell functions J Immunol 184 11 Jun 1 2010 5969 5979
51. L. Bracci, V. La Sorsa, F. Belardelli, and E. Proietti Type I interferons as vaccine adjuvants against infectious diseases and cancer Expert Rev Vaccines 7 3 Apr 2008 373 381 (Pubitemid 351520025)
52. T. Tüting, C.C. Wilson, D.M. Martin, Y.L. Kasamon, J. Rowles, and D.I. Ma Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha J Immunol 160 3 Feb 1 1998 1139 1147 (Pubitemid 28093408)
53. L. Li, J. Kim, and V.A. Boussiotis IL-1β-mediated signals preferentially drive conversion of regulatory T cells but not conventional T cells into IL-17-producing cells J Immunol 185 7 Oct 1 2010 4148 4153